Literature DB >> 8627008

Histochemistry to detect Helix pomatia lectin binding in breast cancer: methodology makes a difference.

S A Brooks1, M Lymboura, U Schumacher, A J Leathem.   

Abstract

A number of studies have shown that altered cellular glycosylation, as detected by binding of Helix pomatia lectin to paraffin sections, is associated with metastatic disease and consequent poor patient prognosis in breast and other cancers. In a 24-year retrospective study, sections of 373 primary breast cancers were stained for binding of the lectin using two different histochemical techniques: a direct method (using peroxidase-conjugated lectin) and an indirect method (using native, unconjugated lectin). Similar percentages of cases were positive (79%) and negative (21%) for lectin binding with either technique, but there was enormous inconsistency when individual cases were examined. A total of 38/373 (10.2%) cases that were negative by the indirect method were positive by the direct method, and 37/373 (9.9%) cases that were negative by the direct method were positive by the indirect method. Life tables calculated for lectin staining vs nonstaining cases showed a very strong correlation between lectin binding and long-term survival (p < 0.0001) when staining was performed by the indirect method, but only very weak correlation with prognosis (p < 0.03, borderline significance) when the direct technique was employed. SDS-PAGE revealed that there were differences in breast cancer glycoproteins recognized by native lectin and peroxidase-conjugated lectin immobilized on Sepharose 4B affinity beads. Helix pomatia lectin binding appears to be an intriguing and potentially valuable marker of biological behavior in breast cancer. This study emphasizes the importance of selecting an appropriate immunohistochemical technique for its visualization.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8627008     DOI: 10.1177/44.5.8627008

Source DB:  PubMed          Journal:  J Histochem Cytochem        ISSN: 0022-1554            Impact factor:   2.479


  8 in total

1.  Is the lectin binding pattern of human breast and colon cancer cells influenced by modulators of sialic acid metabolism?

Authors:  U Schumacher; D Mukhtar; P Stehling; W Reutter
Journal:  Histochem Cell Biol       Date:  1996-12       Impact factor: 4.304

2.  Helix pomatia agglutinin binding glycoproteins in thyroid tumors.

Authors:  Rajeev Parameswaran; Gregory Sadler; Susan Brooks
Journal:  World J Surg       Date:  2011-10       Impact factor: 3.352

3.  Lectin histochemistry of resected adenocarcinoma of the lung: helix pomatia agglutinin binding is an independent prognostic factor.

Authors:  Eckart Laack; Haleh Nikbakht; Anja Peters; Christian Kugler; Yvonne Jasiewicz; Lutz Edler; Dieter Kurt Hossfeld; Udo Schumacher
Journal:  Am J Pathol       Date:  2002-03       Impact factor: 4.307

4.  Clinically proven markers of metastasis predict metastatic spread of human melanoma cells engrafted in scid mice.

Authors:  A Thies; S Mauer; O Fodstad; U Schumacher
Journal:  Br J Cancer       Date:  2007-01-30       Impact factor: 7.640

5.  GalNAc glycoprotein expression by breast cell lines, primary breast cancer and normal breast epithelial membrane.

Authors:  S A Brooks; D M Hall; I Buley
Journal:  Br J Cancer       Date:  2001-09-28       Impact factor: 7.640

6.  Lectin binding to cutaneous malignant melanoma: HPA is associated with metastasis formation.

Authors:  A Thies; I Moll; J Berger; U Schumacher
Journal:  Br J Cancer       Date:  2001-03-23       Impact factor: 7.640

7.  E-/P-selectins and colon carcinoma metastasis: first in vivo evidence for their crucial role in a clinically relevant model of spontaneous metastasis formation in the lung.

Authors:  S Köhler; S Ullrich; U Richter; U Schumacher
Journal:  Br J Cancer       Date:  2009-12-15       Impact factor: 7.640

8.  Identification of O-Linked Glycoproteins Binding to the Lectin Helix pomatia Agglutinin as Markers of Metastatic Colorectal Cancer.

Authors:  Diluka Peiris; Marlène Ossondo; Simon Fry; Marilena Loizidou; Juliette Smith-Ravin; Miriam V Dwek
Journal:  PLoS One       Date:  2015-10-23       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.